Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
CTMX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.75 - $5.85
Previous CloseN/A
Volume1.08M
Average Volume (3M)904.63K
Market Cap
$62.23M
Enterprise Value-$6.45M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)4.7
Beta1.65
Next Earnings
Feb 26, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding78,258,880
10 Day Avg. Volume710,857
30 Day Avg. Volume904,625
Standard Deviation0.20
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.49
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.06
Enterprise Value/Ebitda-0.80
Forecast
1Y Price Target
$4.69Price Target Upside486.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
CytomX Therapeutics News
PremiumCompany Announcements
CytomX Therapeutics Announces Executive Departure and Severance
PremiumCompany Announcements
CytomX Therapeutics Reports Q3 Progress and Growth---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCytomX reported its 3Q24 financials, recording a net profit of $0.07 per share for the period vs. prior estimate of net loss of $0.09 per share.
PartnershipsDiscovery-stage research collaborations with major pharmaceutical companies like Amgen, Astellas, Bristol-Myers Squibb, Moderna, and Regeneron remain ongoing.
Pipeline DevelopmentCX-801 Phase 1 trial starts patient dosing and is designed to evaluate safety and signs of clinical activity as monotherapy and in combination with Merck & Co.'s marketed anti-PD-1 therapy KEYTRUDA (pembrolizumab).
Bears Say
Clinical ChallengesDevelopment in pancreatic cancer has historically faced numerous clinical challenges.
Clinical RisksRisks include emergence of unexpected side effects with CX-904, CX-2051, CX-801, or probody T-cell bispecifics in future clinical data.
Market ReactionThe net reaction to the earnings call presentation led to a significant drop in stock price, settling at -35% since regular trading.
---
Ownership Overview
2.56% Insiders
7.93% Mutual Funds
29.07% Other Institutional Investors
55.04% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CTMX FAQ
What was CytomX Therapeutics Inc’s price range in the past 12 months?
CytomX Therapeutics Inc lowest stock price was $0.75 and its highest was $5.85 in the past 12 months.
What is CytomX Therapeutics Inc’s market cap?
CytomX Therapeutics Inc’s market cap is $62.23M.
When is CytomX Therapeutics Inc’s upcoming earnings report date?
CytomX Therapeutics Inc’s upcoming earnings report date is Feb 26, 2025 which is in 5 days.
How were CytomX Therapeutics Inc’s earnings last quarter?
CytomX Therapeutics Inc released its earnings results on Nov 07, 2024. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.172 by $0.242.
Is CytomX Therapeutics Inc overvalued?
According to Wall Street analysts CytomX Therapeutics Inc’s price is currently Undervalued.
Does CytomX Therapeutics Inc pay dividends?
CytomX Therapeutics Inc does not currently pay dividends.
What is CytomX Therapeutics Inc’s EPS estimate?
CytomX Therapeutics Inc’s EPS estimate is -0.2.
How many shares outstanding does CytomX Therapeutics Inc have?
CytomX Therapeutics Inc has 78,258,880 shares outstanding.
What happened to CytomX Therapeutics Inc’s price movement after its last earnings report?
CytomX Therapeutics Inc reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.172. Following the earnings report the stock price went up 9%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc?
Currently, no hedge funds are holding shares in CTMX
---
CytomX Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.69 (486.25% Upside)
$4.69 (486.25% Upside)
Blogger Sentiment
Bullish
CTMX Sentiment 75%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.57%
12-Months-Change
Fundamentals
Return on Equity
-58.97%
Trailing 12-Months
Asset Growth
-37.16%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
---
CTMX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced sentiment. While there were significant achievements in revenue growth, pipeline progress, and strong collaborations, there were also concerns over increased expenses and delays in key clinical decisions.Read More>---
CTMX Stock 12 Month Forecast
Average Price Target
$4.69
▲(486.25% Upside)
Technical Analysis
Xoma
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Blueprint Medicines
―
Adaptimmune Therapeutics
―
Best Analysts Covering CTMX
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-16.55%
reiterated a buy rating 2 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -16.55% per trade.
---